Literature DB >> 16850908

Modulation of serum concentrations of melatonin by carbamazepine and valproate.

Madhur Gupta1, Kamlesh Kohli, Y K Gupta.   

Abstract

Evidence has accumulated about the involvement of reactive oxygen species (ROS) in epilepsy. The neuromodulator melatonin has been shown to reduce oxidative stress in various animal models due to its free radical scavenging properties. The present study investigated whether carbamazepine and valproate alter serum concentrations of melatonin. Epileptic children were randomly assigned to receive carbamazepine/ valproate monotherapy till 22 patients were recruited in the study. At the tenth day, in the evening, samples were drawn for baseline endogenous melatonin estimation. The patients were then administered exogenous melatonin, and repeat samples were drawn after 30 minutes. Serum levels of melatonin were estimated using Melatonin ELISA kits. The median levels of melatonin were 165.0 pg/ml (Range 50.0-350.0) in CBZ+MEL group and 78.0 pg/ml (Range 13.0-260.0) in the VPA+MEL group. The observed difference in melatonin levels could be attributed to the difference in antiepileptic drugs, additive increase in reactive oxygen species due to disease combined with carbamazepine, or possibly to a difference in melatonin kinetics in conditions of oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16850908

Source DB:  PubMed          Journal:  Indian J Physiol Pharmacol        ISSN: 0019-5499


  4 in total

Review 1.  Carbamazepine versus valproate monotherapy for epilepsy.

Authors:  A G Marson; P R Williamson; J L Hutton; H E Clough; D W Chadwick
Journal:  Cochrane Database Syst Rev       Date:  2000

2.  Circadian Profile of Salivary Melatonin Secretion in Hypoxic Ischemic Encephalopathy.

Authors:  Łukasz Kapek; Justyna Paprocka; Marek Kijonka; Maria Zych; Ewa Emich-Widera; Beata Rzepka-Migut; Damian Borys; Ilona Kaczmarczyk-Sedlak; Maria Sokół
Journal:  Int J Endocrinol       Date:  2020-09-25       Impact factor: 3.257

3.  Melatonin and melatonin agonists to prevent and treat delirium in critical illness: a systematic review protocol.

Authors:  Jennifer Foster; Lisa D Burry; Lehana Thabane; Karen Choong; Kusum Menon; Mark Duffett; Alexandra Cheung; Melanie Guenette; Timothy Chimunda; Louise Rose
Journal:  Syst Rev       Date:  2016-11-24

Review 4.  Melatonin-Measurement Methods and the Factors Modifying the Results. A Systematic Review of the Literature.

Authors:  Beata Rzepka-Migut; Justyna Paprocka
Journal:  Int J Environ Res Public Health       Date:  2020-03-15       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.